Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 56Breast Neoplasms 49Ovarian Neoplasms 31Triple Negative Breast Neoplasms 27Endometrial Neoplasms 25Lung Neoplasms 24Fallopian Tube Neoplasms 22Neoplasm Metastasis 21Squamous Cell Carcinoma of Head and Neck 19Parkinson Disease 4, Autosomal Dominant Lewy Body 18Neoplasms 14Esophageal Squamous Cell Carcinoma 12Esophageal Neoplasms 12Carcinoma, Ovarian Epithelial 9Stomach Neoplasms 8Head and Neck Neoplasms 8Colorectal Neoplasms 8Carcinoma 7Adenocarcinoma Of Esophagus 7Peritoneal Neoplasms 6Adenocarcinoma 6Uterine Cervical Neoplasms 5Melanoma 5Oropharyngeal Neoplasms 4Cholangiocarcinoma 4Carcinoma, Transitional Cell 4Small Cell Lung Carcinoma 3Recurrence 3Pancreatic Neoplasms 3Mouth Neoplasms 3

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Mucinous Adenocarcinoma × Paclitaxel × 90 days × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡